Literature DB >> 20959502

Cerebrospinal fluid penetration of high-dose daptomycin in suspected Staphylococcus aureus meningitis.

M Shawn Riser1, Christopher M Bland, Celeste N Rudisill, P Brandon Bookstaver.   

Abstract

OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE
SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin/tazobactam. Blood cultures revealed S. aureus susceptible to oxacillin. Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed acute renal failure (serum creatinine 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission). The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of cardiac arrest on day 10. The patient experienced relapsing MSSA bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) infection. Nafcillin was discontinued and daptomycin 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's death on day 16. Daptomycin serum and CSF trough concentrations were 11.21 μg/mL and 0.52 μg/mL, respectively, prior to the third dose. Lumbar puncture results were inconclusive and no further blood cultures were positive for MSSA. Creatine kinase levels were normal prior to daptomycin therapy and were not reassessed. DISCUSSION: Daptomycin was initiated in our patient secondary to possible nafcillin-induced acute interstitial nephritis and relapsing bacteremia. At a dose of 9 mg/kg, resultant penetration of 5% was higher than in previous reports, more consistent with inflamed meninges.
CONCLUSIONS: High-dose daptomycin may be an alternative option for MSSA bacteremia with or without a CNS source in patients who have failed or cannot tolerate standard therapy. Further clinical evaluation in patients with confirmed meningitis is warranted.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20959502     DOI: 10.1345/aph.1P307

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  7 in total

1.  Adjunctive daptomycin attenuates brain damage and hearing loss more efficiently than rifampin in infant rat pneumococcal meningitis.

Authors:  Denis Grandgirard; Melchior Burri; Philipp Agyeman; Stephen L Leib
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

2.  Case report of a successful treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and MRSA/vancomycin-resistant Enterococcus faecium cholecystitis by daptomycin.

Authors:  Carlo Tascini; Antonello Di Paolo; Marialuisa Polillo; Mauro Ferrari; Paola Lambelet; Romano Danesi; Francesco Menichetti
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

3.  A Systematic Review of Studies Reporting Antibiotic Pharmacokinetic Data in the Cerebrospinal Fluid of Critically Ill Patients with Uninflamed Meninges.

Authors:  Nilesh Kumta; Jason A Roberts; Jeffrey Lipman; Wai Tat Wong; Gavin M Joynt; Menino Osbert Cotta
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

4.  Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections.

Authors:  Ravina Kullar; Judy N Chin; David J Edwards; Dennis Parker; William M Coplin; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

Review 5.  Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?

Authors:  Nilesh Kumta; Jason A Roberts; Jeffrey Lipman; Menino Osbert Cotta
Journal:  Clin Pharmacokinet       Date:  2018-04       Impact factor: 6.447

Review 6.  Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.

Authors:  Amanda K Sullins; Susan M Abdel-Rahman
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

Review 7.  Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.

Authors:  Antonello Di Paolo; Giovanni Gori; Carlo Tascini; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.